Annexon, Inc. Share Price
ANNXAnnexon, Inc. Stock Performance
Open $4.68 | Prev. Close $4.74 | Circuit Range N/A |
Day Range $4.68 - $4.91 | Year Range $1.85 - $7.16 | Volume 35,997 |
Average Traded $4.82 |
Annexon, Inc. Share Price Chart
About Annexon, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Annexon, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
09-Jun-26 | $5.26 | $5.19 | +1.57% |
08-Jun-26 | $5.34 | $5.11 | -3.22% |
05-Jun-26 | $5.40 | $5.28 | -3.03% |
04-Jun-26 | $5.41 | $5.45 | +1.40% |
03-Jun-26 | $5.25 | $5.37 | +2.09% |
02-Jun-26 | $5.28 | $5.26 | -5.40% |
01-Jun-26 | $5.64 | $5.56 | +2.77% |